Chemotherapeutic agents are powerful drugs used to fight cancer by targeting rapidly dividing cells. Because they can't fully distinguish between cancerous and healthy rapidly dividing cells, they come with significant side effects that nurses need to anticipate and manage. This section covers safe handling, drug classes and mechanisms, administration methods, and the nursing considerations that keep patients safe during treatment.
Safe Handling and Administration of Chemotherapeutic Agents
Safe handling of chemotherapeutic agents
Chemotherapy drugs are cytotoxic, meaning they're hazardous not just to patients but to anyone who comes in contact with them. Nurses who handle these agents without proper precautions risk absorbing small amounts through skin contact, inhalation, or accidental splashes.
- Wear full personal protective equipment (PPE): chemotherapy-rated gowns, gloves, masks, and eye protection. Always double glove when handling these agents, since a single layer may not provide adequate protection against permeation.
- Prepare medications in a biological safety cabinet (BSC) or closed-system transfer device. These contain aerosols and vapors that would otherwise escape into the room.
- Dispose of all contaminated materials (gloves, tubing, IV bags, gauze) in leak-proof containers labeled as hazardous waste, following your facility's specific disposal protocols.
- Clean up spills immediately using a chemotherapy spill kit (absorbent pads, PPE, waste bags). Notify the appropriate personnel and document the incident per facility policy.
- Educate patients and caregivers on safe handling at home: wear gloves when handling bodily fluids or contaminated linens for at least 48 hours after treatment, wash hands thoroughly after any contact, and dispose of contaminated materials as directed by the healthcare team.
Methods and routes of chemotherapy administration
Chemotherapy isn't one-size-fits-all. The dosing strategy and route of administration are chosen based on the cancer type, treatment goals, and the patient's overall condition.
Dosing strategies:
- Conventional chemotherapy is given at the maximum tolerated dose to achieve the greatest cancer cell kill in each cycle.
- Dose-dense chemotherapy shortens the intervals between treatment cycles (e.g., every 2 weeks instead of every 3), reducing the time cancer cells have to regrow between doses.
- Metronomic chemotherapy uses low, frequent doses to maintain a constant drug level in the body. This approach also targets tumor blood vessel growth (angiogenesis).
Treatment phases:
- Induction phase: Initial high-dose treatment designed to achieve remission by rapidly destroying the bulk of cancer cells.
- Consolidation phase: Additional treatment cycles after remission to eliminate remaining cancer cells and reduce relapse risk.
- Maintenance phase: Long-term, lower-dose treatment to suppress any residual cancer cell growth and sustain remission.
Routes of administration:
- Intravenous (IV): Delivers chemotherapy directly into the bloodstream for systemic distribution. This is the most common route.
- Oral: Taken by mouth as a pill, capsule, or liquid. Convenient for patients but requires strict adherence to the prescribed schedule.
- Intramuscular (IM): Injected into muscle tissue for gradual absorption into the bloodstream.
- Subcutaneous (SC): Injected into the fatty tissue beneath the skin for slow, steady absorption.
- Intrathecal: Administered directly into the cerebrospinal fluid (CSF) to treat cancers involving the central nervous system, since most IV chemotherapy drugs can't cross the blood-brain barrier.
- Topical: Applied to the skin as a cream or ointment for localized treatment of skin cancers (e.g., 5-fluorouracil cream for actinic keratoses).
Chemotherapeutic Agents and Nursing Considerations
Side effects of chemotherapeutic drugs
Most chemotherapy side effects stem from one core problem: these drugs target all rapidly dividing cells, not just cancer cells. That means tissues with naturally high turnover rates (bone marrow, GI lining, hair follicles) take the hardest hit.
- Myelosuppression: Decreased bone marrow production of blood cells, leading to anemia (low RBCs), neutropenia (low WBCs, increasing infection risk), and thrombocytopenia (low platelets, increasing bleeding risk). The nadir (lowest blood cell count) typically occurs 7–14 days after treatment.
- GI effects: Nausea, vomiting, diarrhea, and mucositis (painful inflammation and ulceration of the mucous membranes) result from damage to the rapidly dividing cells lining the GI tract.
- Alopecia: Hair loss occurs because hair follicle cells divide rapidly. This is usually temporary, and hair typically regrows after treatment ends.
- Fatigue: One of the most common complaints. It results from the body's immune response to treatment, anemia, poor nutrition, and the energy demands of tissue repair.
- Skin changes: Dryness, rash, photosensitivity, and hyperpigmentation can occur.
- Peripheral neuropathy: Numbness, tingling, and pain in the hands and feet caused by nerve damage. This is especially common with plant alkaloids (vincristine) and platinum-based agents. It may be irreversible.
- Cognitive changes ("chemo brain"): Difficulty with memory, concentration, and multitasking that can persist well beyond treatment.
- Fertility issues: Damage to reproductive cells can cause temporary or permanent infertility. This should be discussed before treatment begins.
- Secondary malignancies: DNA damage from chemotherapy can lead to new cancers developing years later, particularly with alkylating agents.
Classes of chemotherapeutic agents
Each class of chemotherapy drug disrupts cancer cell growth through a different mechanism. Knowing the class helps you anticipate the specific side effects your patient is most likely to experience.
- Alkylating agents (cyclophosphamide, ifosfamide): Add alkyl groups directly to DNA strands, causing cross-links that prevent the cell from replicating. These are cell cycle–nonspecific, meaning they can damage cells in any phase. A unique risk with cyclophosphamide is hemorrhagic cystitis (bladder inflammation), which is why adequate hydration and the protectant drug mesna are often used.
- Antimetabolites (5-fluorouracil, methotrexate): Structurally mimic normal metabolites needed for DNA and RNA synthesis. When the cell incorporates these "fakes," synthesis stalls. These are most effective during the S phase (DNA synthesis) of the cell cycle.
- Plant alkaloids (vincristine, paclitaxel): Disrupt microtubule function, which is essential for mitotic spindle formation during cell division. Vincristine prevents microtubule assembly, while paclitaxel stabilizes microtubules so they can't disassemble. Both block mitosis. These are M phase–specific and carry a high risk of peripheral neuropathy.
- Antitumor antibiotics (doxorubicin, bleomycin): Interfere with DNA replication through several mechanisms, including intercalating (inserting) between DNA base pairs and generating free radicals that damage DNA. Doxorubicin carries a risk of cardiotoxicity (cumulative lifetime dose must be tracked). Bleomycin carries a risk of pulmonary toxicity (monitor lung function).
- Topoisomerase inhibitors (etoposide, irinotecan): Block topoisomerase enzymes that normally unwind and repair DNA during replication. Without these enzymes, DNA strands break and the cell can't divide.
- Targeted therapies (imatinib, trastuzumab): Unlike traditional chemotherapy, these drugs target specific molecules or signaling pathways that drive cancer cell growth. Imatinib blocks the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Trastuzumab targets HER2 receptors in HER2-positive breast cancer. Side effect profiles differ from traditional chemo because they're more selective.
Nursing considerations for chemotherapy
- Assess understanding: Before treatment, confirm that the patient understands the purpose of therapy, expected side effects, and the treatment timeline. This supports informed consent and adherence.
- Verify the "rights": Check the correct drug, dose, route, time, and patient identity. Many facilities require two-nurse independent verification for chemotherapy orders because of the high-risk nature of these drugs.
- Monitor during infusion: Watch for infusion reactions (flushing, urticaria, dyspnea, hypotension), especially during the first dose of a new agent. Have emergency medications readily available.
- Manage side effects proactively: Administer antiemetics before and after treatment as ordered (not just when the patient feels nauseated). Provide oral care protocols for mucositis prevention. Encourage adequate nutrition and rest.
- Practice strict infection control: Patients with neutropenia are at high risk for life-threatening infections. Monitor temperature closely, enforce hand hygiene, and educate the patient to report fever (≥100.4°F / 38°C) immediately.
- Monitor labs: Track CBC with differential before each cycle. Treatment may be delayed if the absolute neutrophil count (ANC) or platelet count is too low.
- Document thoroughly: Record the drug administered, dose, route, infusion time, patient response, and any adverse effects. Accurate documentation supports continuity of care.
Patient education for chemotherapy
- Explain the treatment schedule, what to expect during each session, and the most likely side effects for their specific regimen.
- Teach side effect management: dietary modifications for nausea and diarrhea (small frequent meals, bland foods, adequate hydration), proper oral hygiene to prevent mucositis (soft toothbrush, alcohol-free mouthwash, frequent rinsing), and strategies for managing fatigue (balancing rest with light activity).
- Stress infection prevention: frequent handwashing, avoiding large crowds and sick contacts, and reporting any fever of ≥100.4°F (38°C) immediately. Patients should check with their provider before receiving any vaccines during treatment.
- Discuss fertility preservation options before treatment starts (sperm banking, egg freezing), since some regimens cause permanent infertility.
- Provide resources for emotional and psychological support, including counseling, support groups, and social work referrals.
- Encourage patients to communicate openly with the healthcare team about new symptoms, concerns, or difficulties with adherence.
- Reinforce the importance of regular follow-up appointments for lab monitoring, treatment response assessment, and ongoing side effect management.
Mechanisms of chemotherapeutic agents
The choice of chemotherapy drug depends on the specific cancer type, stage, tumor grade, and patient factors (organ function, comorbidities, performance status). Different classes target different points in the cell's life cycle:
- Alkylating agents directly damage DNA through cross-linking (cell cycle–nonspecific)
- Antimetabolites interfere with DNA/RNA synthesis during the S phase
- Plant alkaloids disrupt mitotic spindle formation during the M phase
- Antitumor antibiotics intercalate with DNA and generate free radicals
- Topoisomerase inhibitors prevent DNA unwinding and repair during replication
- Targeted therapies block specific signaling pathways that drive cancer cell growth
Drug interactions are a major safety concern with chemotherapy:
- Cytochrome P450 inhibitors or inducers can alter how quickly chemotherapy drugs are metabolized, potentially increasing toxicity or reducing effectiveness.
- Combining chemotherapy with other myelosuppressive agents increases the risk of severe bone marrow suppression.
- Some targeted therapies have enhanced or reduced efficacy when combined with certain other drugs.
- Always consult current drug references and your pharmacist for specific interaction information before administering chemotherapy.
Chemotherapy and the Cell Cycle
Understanding these key terms helps connect how chemotherapy drugs work to the clinical decisions made during treatment:
- Cell cycle: The sequence of phases a cell goes through to divide (G1 → S → G2 → M). Different chemotherapy classes target different phases. Cell cycle–specific drugs (like antimetabolites and plant alkaloids) work best on actively dividing cells. Cell cycle–nonspecific drugs (like alkylating agents) can damage cells in any phase, including resting cells.
- Cytotoxicity: The ability of a drug to kill cells. Chemotherapy achieves cytotoxicity by disrupting the cell cycle or triggering apoptosis (programmed cell death).
- Drug resistance: Cancer cells can develop ways to survive chemotherapy, such as pumping the drug out of the cell, repairing DNA damage more efficiently, or mutating the drug's target. This is why combination chemotherapy (using drugs from different classes) is often more effective than a single agent.
- Pharmacokinetics: How the body absorbs, distributes, metabolizes, and excretes a drug. This determines dosing, scheduling, and which organs are most at risk for toxicity.
- Tumor markers: Substances (proteins, enzymes, hormones) produced by cancer cells or by the body in response to cancer. Examples include PSA (prostate cancer) and CA-125 (ovarian cancer). These are used to monitor treatment response, not to diagnose cancer on their own.
- Adjuvant therapy: Chemotherapy given after primary treatment (usually surgery) to eliminate any remaining microscopic cancer cells and reduce recurrence risk.
- Neoadjuvant therapy: Chemotherapy given before primary treatment to shrink the tumor, making surgery more feasible or less extensive.